<DOC>
	<DOCNO>NCT00003150</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know combination chemotherapy effective without rituximab non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without rituximab treat old patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Monoclonal Antibody Therapy Treating Older Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisone ) without rituximab older patient diffuse mixed , diffuse large , immunoblastic large cell non-Hodgkin 's lymphoma B-cell lineage respect response rate , time treatment failure , toxicity , survival . II . Compare efficacy maintenance therapy consist rituximab vs observation alone initial therapy respect time treatment failure , duration response , toxicity , survival patient population . III . Determine maintenance therapy rituximab result conversion partial response complete response . OUTLINE : This randomize study . For first randomization , patient stratify accord number risk factor ( 0-1 v 2-4 ) . For second randomization , addition number risk factor , patient stratify accord objective response initial induction therapy ( partial response vs complete response ) induction therapy ( CHOP vs CHOP rituximab ) . Patients randomize one two treatment arm . Arm I : Patients receive CHOP chemotherapy comprise cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 oral prednisone day 1-5 . Treatment repeat every 21 day absence unacceptable toxicity . Arm II : Patients receive treatment arm I . Patients also receive rituximab IV day -7 , -3 , 41 , 83 . Patients achieve complete response ( CR ) 4 course CHOP remain CR 6 course CHOP randomize one two arm . Arm I ( Maintenance therapy ) : Patients receive rituximab IV weekly 4 week . Courses repeat every 6 month 2 year absence unacceptable toxicity . Arm II : Patients observe . Patients achieve partial response ( PR ) 6 course OR PR 4 course CR 6 course receive 2 additional course CHOP therapy . Patients also randomize receive either maintenance therapy observation . Patients stable disease disease progression remove study . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 630 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven intermediate high grade Bcell nonHodgkin 's lymphoma ( Burkitt 's , nonBurkitt 's , undifferentiated , lymphoblastic lymphoma ) Bcell nonHodgkin 's lymphoma positive CD19 and/or CD20 slidebased immunohistochemistry flow cytometry No mantle cell follicular lymphoma Measurable disease , define least one following : Physical examination Radiographic finding least 2 dimension Bidimensional measurable defect mass measure least 2 cm diameter radionuclide CT scan Enlarged spleen extend least 2 cm costal margin provide likely explanation besides lymphomatous involvement Enlarged liver extend least 5 cm costal margin along biopsyproven lymphomatous hepatic involvement No history transform lymphoma No known posttransplantation lymphoproliferative disorder No CNS involvement CALGB patient 6065 year age must eligible study high priority A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : See Disease Characteristics 60 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 ( unless due lymphoma ) Platelet count great 100,000/mm3 ( unless due lymphoma ) Hepatic : Bilirubin great 3.0 mg/dL Renal : Creatinine le 2.1 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No active heart disease include congestive heart failure , myocardial infarction within past 3 month , symptomatic ventricular arrhythmia LVEF least 45 % prior history heart disease exist Other : HIV negative No malignancy within past 5 year except squamous cell basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior biologic response modifier therapy No prior immunotherapy No prior rituximab Chemotherapy : No prior cytotoxic chemotherapy No concurrent dexrazoxane Endocrine therapy : Prior corticosteroid allow Radiotherapy : No prior radiotherapy No prior radioimmunotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
</DOC>